• Product NameLenalidomide (CC-5013)
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityLenalidomide (initially known as CC-5013 and marketed as Revlimid? by Celgene) is a derivative of thalidomide introduced in 2004. It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic modality, but has also shown efficacy in the hematological disorders known as the myelodysplastic syndromes. FDA approved on December 27, 2005.
• Target NameTNF inhibitor
• CAS No. 191732-72-6
• Calculated MW 259.26
• Formulation C13H13N3O3
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
  Pathways:Apoptosis
  Receptor:TNF-α
  Boling pt:
  Melting pt:269-271C
  Solubility:DMSO: 35 mg/mL
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Muller GW, et al. Bioorg Med Chem Lett, 1999, 9(11), 1625-1630.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting